Champions Oncology (CSBR) stock price, revenue, and financials

Champions Oncology market cap is $116 m, and annual revenue was $27.07 m in FY 2019

$116 M

CSBR Mkt cap, 29-May-2020

$9 M

Champions Oncology Revenue Q3, 2020
Champions Oncology Gross profit (Q3, 2020)4.7 M
Champions Oncology Gross profit margin (Q3, 2020), %52%
Champions Oncology Net income (Q3, 2020)407 K
Champions Oncology EBIT (Q3, 2020)433 K
Champions Oncology Cash, 31-Jan-20203.3 M
Champions Oncology EV116.5 M

Champions Oncology Income Statement

Quarterly

USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

1.6m1.7m2.4m2.1m1.5m2.9m3.0m2.4m3.7m1.9m1.9m1.8m2.8m3.0m2.6m3.7m4.5m3.6m5.0m5.2m5.1m6.2m6.7m6.4m6.7m7.6m9.0m

Cost of goods sold

3.1m3.5m3.4m3.8m3.9m4.3m

Gross profit

3.1m3.2m3.0m3.0m3.7m4.7m

Gross profit Margin, %

50%48%47%44%49%52%

Sales and marketing expense

688.0k651.0k623.0k709.0k680.0k658.0k642.0k698.0k821.0k1.0m1.2m1.1m1.0m834.0k779.0k925.0k717.0k726.0k683.0k551.0k627.0k518.0k740.0k879.0k870.0k977.0k1.3m

R&D expense

541.0k1.0m930.0k387.0k436.0k592.0k402.0k677.0k535.0k1.4m1.2m1.1m1.1m919.0k999.0k1.2m1.0m998.0k1.1m1.1m1.0m1.1m1.2m1.3m1.3m1.3m1.4m

General and administrative expense

1.7m1.5m1.3m1.1m1.2m1.1m1.1m1.3m2.1m1.5m1.4m1.1m1.3m1.7m1.0m1.5m1.0m836.0k1.2m954.0k1.0m1.1m1.0m1.2m1.4m1.1m1.6m

Operating expense total

2.9m3.1m2.8m2.2m2.3m2.4m2.1m2.7m3.5m3.9m3.8m3.3m3.4m3.5m2.8m3.7m2.7m2.6m3.0m2.6m2.7m2.7m3.0m3.4m3.6m3.5m4.3m

EBIT

(2.2m)(2.5m)(1.8m)(1.6m)(1.9m)(720.0k)(766.0k)(1.7m)(1.4m)(3.7m)(3.7m)(3.4m)(2.9m)(2.5m)(2.4m)(2.5m)(493.0k)(1.4m)(619.0k)(70.0k)(67.0k)481.0k275.0k(370.0k)(614.0k)291.0k433.0k

EBIT margin, %

(135%)(142%)(74%)(76%)(131%)(25%)(25%)(71%)(38%)(195%)(195%)(187%)(103%)(84%)(93%)(69%)(11%)(39%)(12%)(1%)(1%)8%4%(6%)(9%)4%5%

Interest expense

177.0k120.0k54.0k279.0k57.0k265.0k1.5m614.0k839.0k186.0k598.0k615.0k10.0k14.0k8.0k9.0k16.0k8.0k51.0k13.0k7.0k1.0k7.0k1.0k12.0k

Interest income

10.0k6.0k5.0k

Pre tax profit

(2.0m)(2.3m)(1.7m)(1.3m)(1.0k)(985.0k)(2.2m)(2.3m)(569.0k)(3.5m)(3.1m)(2.8m)(2.9m)(2.5m)(2.4m)(2.5m)(509.0k)(1.4m)(670.0k)(83.0k)(74.0k)482.0k268.0k(369.0k)(626.0k)318.0k419.0k

Income tax expense

3.0k5.0k3.0k3.0k5.0k5.0k10.0k12.0k6.0k41.0k31.0k14.0k(5.0k)4.0k11.0k2.0k1.0k15.0k11.0k12.0k

Net Income

(2.0m)(2.3m)(1.7m)(1.3m)(2.0m)(990.0k)(2.2m)(2.3m)(574.0k)(3.5m)(3.1m)(2.8m)(2.9m)(2.5m)(2.4m)(2.5m)(504.0k)(1.4m)(674.2k)(94.0k)(76.0k)482.0k267.0k(369.0k)(641.0k)307.0k407.0k

Champions Oncology Balance Sheet

Annual

USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

4.8m9.6m5.9m9.4m3.3m856.0k3.2m

Accounts Receivable

584.0k500.0k1.3m1.1m1.3m2.3m3.9m4.4m

Prepaid Expenses

205.0k315.0k383.0k346.0k300.0k287.0k308.0k

Inventories

443.0k

Current Assets

5.5m10.4m7.6m10.8m4.3m5.9m5.1m7.9m

PP&E

560.0k414.0k434.0k452.0k618.0k1.2m2.1m2.5m

Goodwill

669.0k669.0k669.0k669.0k669.0k669.0k669.0k669.0k

Total Assets

6.9m11.7m8.9m12.0m5.8m8.0m8.1m11.3m

Accounts Payable

1.7m1.2m981.0k1.4m1.9m1.9m2.2m2.8m

Short-term debt

16.0k

Current Liabilities

3.5m2.9m3.7m3.8m5.3m7.4m7.5m8.0m

Long-term debt

Total Debt

16.0k

Total Liabilities

4.0m4.0m5.7m4.0m5.5m7.6m8.1m9.0m

Common Stock

38.0k39.0k70.0k108.0k11.0k11.0k12.0k

Preferred Stock

Additional Paid-in Capital

21.2m23.6m43.3m61.2m63.9m71.0m72.1m72.9m

Retained Earnings

(25.1m)(31.5m)(38.9m)(52.0m)(62.5m)(69.3m)(70.8m)(70.7m)

Total Equity

(5.3m)(9.2m)3.2m8.1m238.0k400.0k3.0k2.2m

Financial Leverage

-1.3 x-1.3 x2.8 x1.5 x24.3 x20 x2.7 k x5 x

Quarterly

USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

8.8m7.1m6.5m2.9m2.2m10.8m7.4m7.6m5.8m3.1m575.0k182.0k6.8m4.2m3.3m4.5m4.3m3.5m400.0k700.0k1.1m1.0m2.0m3.3m2.2m2.8m3.3m

Accounts Receivable

1.2m832.0k497.0k639.0k627.0k642.0k1.8m1.5m3.1m925.0k1.1m1.1m1.5m1.9m2.1m1.6m1.9m2.0m2.7m2.6m2.9m3.8m4.7m3.9m3.9m3.9m4.5m

Prepaid Expenses

341.0k328.0k110.0k208.0k95.0k300.0k255.0k219.0k281.0k456.0k393.0k258.0k366.0k295.0k414.0k349.0k445.0k541.0k360.0k303.0k185.0k246.0k262.0k298.0k256.0k363.0k355.0k

Current Assets

10.9m8.8m7.6m3.8m2.9m11.7m9.4m9.3m9.2m4.4m2.1m1.5m8.6m6.3m5.8m6.4m6.7m6.1m3.5m3.5m4.2m5.0m6.9m7.5m6.3m7.1m8.1m

PP&E

212.0k257.0k452.0k525.0k485.0k442.0k404.0k387.0k421.0k411.0k395.0k469.0k445.0k420.0k514.0k590.0k561.0k672.0k2.1m2.0m2.0m2.4m2.5m2.6m3.1m3.1m3.2m

Goodwill

669.0k669.0k669.0k669.0k669.0k669.0k669.0k669.0k669.0k669.0k669.0k669.0k669.0k669.0k669.0k669.0k669.0k669.0k669.0k669.0k669.0k669.0k669.0k669.0k669.0k669.0k669.0k

Total Assets

11.8m9.9m8.9m5.1m4.2m13.0m10.7m10.5m10.5m5.7m3.3m2.8m9.8m7.6m7.1m7.8m8.0m7.5m6.5m6.5m7.1m8.4m10.2m10.9m13.4m13.9m15.1m

Accounts Payable

1.5m1.3m1.6m1.3m1.2m1.1m976.0k982.0k937.0k1.3m1.6m1.4m1.4m1.3m1.5m1.5m1.2m1.3m1.7m1.5m2.0m2.1m2.0m2.1m2.7m2.8m2.2m

Short-term debt

137.0k142.0k224.0k9.0k2.0k490.0k

Current Liabilities

3.8m3.4m3.5m2.6m2.9m2.7m2.2m3.3m3.7m3.4m3.9m6.3m3.8m3.3m4.6m4.4m4.6m5.3m6.0m5.8m6.2m6.9m7.3m7.7m7.9m8.3m8.4m

Long-term debt

148.0k95.0k3.6m3.4m3.3m

Total Debt

285.0k237.0k224.0k3.6m3.4m3.8m

Total Liabilities

4.6m4.1m4.1m2.8m3.3m3.7m4.7m6.4m6.0m5.2m5.2m7.0m3.9m3.5m4.9m4.7m4.8m5.5m6.2m6.1m6.6m7.8m8.2m8.6m11.6m11.8m11.9m

Common Stock

37.0k37.0k38.0k38.0k38.0k39.0k39.0k39.0k70.0k70.0k70.0k70.0k9.0k9.0k9.0k11.0k11.0k11.0k11.0k11.0k11.0k11.0k11.0k12.0k12.0k12.0k12.0k

Preferred Stock

Additional Paid-in Capital

18.8m19.8m20.5m21.9m22.6m23.1m24.1m24.6m42.4m44.1m44.9m45.4m62.1m62.8m63.4m69.4m70.0m70.2m71.6m71.7m71.9m72.2m72.1m72.8m73.1m73.1m73.8m

Retained Earnings

(18.5m)(20.9m)(22.6m)(26.5m)(28.4m)(29.4m)(33.7m)(36.0m)(36.6m)(42.4m)(45.6m)(48.3m)(54.9m)(57.5m)(59.9m)(65.0m)(65.5m)(66.9m)(70.0m)(70.1m)(70.2m)(70.3m)(70.1m)(70.4m)(71.3m)(71.0m)(70.6m)

Total Equity

(992.0k)(2.4m)(3.4m)(5.8m)(7.2m)(7.6m)(10.9m)(12.7m)4.5m439.0k(1.9m)(4.1m)5.9m4.1m2.3m3.2m3.2m2.0m290.0k373.0k472.0k602.0k2.0m2.3m1.7m2.1m3.2m

Financial Leverage

-11.9 x-4.1 x-2.6 x-0.9 x-0.6 x-1.7 x-1 x-0.8 x2.3 x12.9 x-1.8 x-0.7 x1.7 x1.8 x3.2 x2.5 x2.5 x3.7 x22.3 x17.4 x15 x13.9 x5.1 x4.7 x7.7 x6.6 x4.7 x

Champions Oncology Cash Flow

Annual

USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(8.7m)(6.3m)(7.4m)(13.1m)(10.4m)(1.5m)128.0k

Depreciation and Amortization

105.0k203.0k213.0k214.0k156.0k168.0k360.0k606.0k

Accounts Receivable

(825.0k)265.0k(282.0k)(986.0k)(1.6m)(531.0k)

Accounts Payable

96.0k(472.0k)(223.0k)433.0k482.0k(43.0k)301.0k653.0k

Cash From Operating Activities

(5.2m)(4.3m)(3.4m)(9.6m)(6.5m)(2.8m)(1.2m)1.9m

Purchases of PP&E

(519.0k)(57.0k)(234.0k)(119.0k)(322.0k)(766.0k)(1.2m)(834.0k)

Cash From Investing Activities

(519.0k)(57.0k)(234.0k)(114.0k)(322.0k)(766.0k)(1.2m)(834.0k)

Long-term Borrowings

(12.0k)(24.0k)(24.0k)(25.0k)(262.0k)

Cash From Financing Activities

97.0k9.1m21.0k13.2m2.0k4.3m13.0k1.2m

Net Change in Cash

(5.7m)4.8m(3.7m)3.5m(6.8m)710.0k(2.4m)2.2m

Interest Paid

Income Taxes Paid

Quarterly

USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(2.0m)(4.4m)(6.1m)(1.3m)(3.3m)(4.3m)(2.2m)(4.6m)(5.1m)(3.5m)(6.7m)(9.5m)(2.9m)(5.5m)(7.9m)(2.5m)(3.1m)(4.5m)(674.2k)(768.5k)(844.0k)482.0k750.0k381.0k(641.0k)(334.0k)72.0k

Depreciation and Amortization

29.0k49.0k65.0k54.0k103.0k153.0k50.0k102.0k158.0k56.0k110.0k166.0k37.0k76.0k114.0k45.0k87.0k127.0k42.0k132.0k253.0k118.0k269.0k433.0k182.0k360.0k579.0k

Accounts Receivable

(962.0k)(2.6m)400.0k210.0k233.0k(398.0k)(865.0k)(1.1m)(314.0k)(577.0k)(714.0k)(407.0k)(263.0k)(669.0k)148.0k(786.0k)(55.0k)480.0k425.0k(334.0k)

Accounts Payable

(82.0k)(286.0k)43.0k(385.0k)(467.0k)(574.0k)(227.0k)(220.0k)(266.0k)347.0k651.0k381.0k22.0k(76.0k)101.0k(387.0k)(744.0k)(572.0k)(120.0k)(303.0k)124.0k(43.0k)(141.0k)(46.0k)(82.0k)(341.0k)(913.0k)

Cash From Operating Activities

(1.5m)(3.3m)(3.7m)(1.8m)(2.6m)(3.1m)(2.1m)(1.9m)(3.6m)(2.8m)(5.2m)(7.6m)(2.5m)(5.1m)(5.9m)(2.4m)(2.6m)(3.2m)(1.9m)(1.7m)(1.2m)336.0k400.0k1.6m(279.0k)81.0k360.0k

Purchases of PP&E

(95.0k)(160.0k)(371.0k)(19.0k)(28.0k)(35.0k)(40.0k)(76.0k)(164.0k)(33.0k)(71.0k)(84.0k)(29.0k)(44.0k)(176.0k)(17.0k)(30.0k)(181.0k)(910.0k)(942.0k)(1.0m)(211.0k)(486.0k)(693.0k)(749.0k)(522.0k)(693.0k)

Cash From Investing Activities

(95.0k)(160.0k)(371.0k)(19.0k)(28.0k)(35.0k)(40.0k)(76.0k)(164.0k)(33.0k)(71.0k)(84.0k)(29.0k)(44.0k)(176.0k)(17.0k)(30.0k)(181.0k)(910.0k)(942.0k)(1.0m)(211.0k)(486.0k)(693.0k)(749.0k)(522.0k)(693.0k)

Long-term Borrowings

(5.0k)(7.0k)(11.0k)(17.0k)(6.0k)(12.0k)(18.0k)(7.0k)(13.0k)(19.0k)(7.0k)(40.0k)(53.0k)(7.0k)(14.0k)(51.0k)

Cash From Financing Activities

4.0k98.0k98.0k9.2m9.0k2.0k2.0m(25.0k)(29.0k)(35.0k)4.3m4.3m4.3m(7.0k)(13.0k)19.0k35.0k1.0m1.4m(7.0k)(12.0k)378.0k

Net Change in Cash

(1.6m)(3.3m)(4.0m)(1.8m)(2.6m)6.1m(2.2m)(2.0m)(3.7m)(2.8m)(5.3m)(5.7m)(2.6m)(5.2m)(6.1m)1.9m1.7m903.0k(2.9m)(2.6m)(2.2m)160.0k950.0k2.3m(1.0m)(453.0k)45.0k

Champions Oncology Ratios

USDY, 2020

EV/EBIT

269.1 x

EV/CFO

323.7 x

Financial Leverage

4.7 x

Champions Oncology Employee Rating

2.922 votes
Culture & Values
2.6
Work/Life Balance
2.8
Senior Management
2.7
Salary & Benefits
2.9
Career Opportunities
2.8
Source